ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

doi:10.1038/s41586-021-03515-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.

Nature - 1 Jun 2021

Yen Ivana, Shanahan Frances, Lee Jeeyun, Hong Yong Sang, Shin Sang Joon, Moore Amanda R, Sudhamsu Jawahar, Chang Matthew T, Bae Inhwan, Dela Cruz Darlene, Hunsaker Thomas, Klijn Christiaan, Liau Nicholas P D, Lin Eva, Martin Scott E, Modrusan Zora, Piskol Robert, Segal Ehud, Venkatanarayan Avinashnarayan, Ye Xin, Yin Jianping, Zhang Liangxuan, Kim Jin-Soo, Lim Hyeong-Seok, Kim Kyu-Pyo, Kim Yu Jung, Han Hye Sook, Lee Soo Jung, Kim Seung Tae, Jung Minkyu, Hong Yoon-Hee, Noh Young Su, Choi Munjeong, Han Oakpil, Nowicka Malgorzata, Srinivasan Shrividhya, Yan Yibing, Kim Tae Won, Malek Shiva

Abstract excerpt

Although RAF monomer inhibitors (type I.5, BRAF(V600)) are clinically approved for the treatment of BRAFV600-mutant melanoma, they are ineffective in non-BRAFV600 mutant cells1-3. Belvarafenib is a potent and selective RAF dimer (type II) inhibitor that exhibits clinical activity in patients with...

Topics

Animals
Cell Line
Cell Line, Tumor
Drug Resistance, Neoplasm
Female
Humans
Melanoma
Mice
Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Multimerization

Proto-Oncogene Proteins A-raf

raf Kinases

Source

Open in PubMed

Identifiers

PMID: 33953400
DOI: 10.1038/s41586-021-03515-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-33953400-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.